Asteron Life Limited (NZX: SUN) has introduced a grant programme to support advisers in implementing ideas from the recent Million Dollar Round Table (MDRT) conference in Canada. The Asteron Life MDRT Grant Programme offers NZ$5,000 grants to up to four advisers, encouraging them to develop plans that enhance business and customer outcomes.
Tony Arthur, Executive Manager of Life Distribution at Asteron Life, emphasized the importance of attending the annual MDRT conference. "Participating in the MDRT conference equips advisers to excel beyond their usual capabilities. However, without a committed action plan, some of the investment in attending can be wasted," Arthur stated. He believes the new grants will help mitigate this lost opportunity and benefit advisers, their businesses, and the life insurance sector.
Arthur highlighted that advisers who create actionable plans after the event will see significant value. He remarked, "The MDRT Conference provided an abundance of high-quality content, speakers, and best practice sharing. The key to maximizing this value is to focus on one or two implementable ideas rather than overwhelming oneself with too many concepts."
Asteron Life supports the MDRT New Zealand committee in expanding its membership and offering opportunities for financial advisers to participate in both local and international events. Arthur noted, "It's crucial for advisers to reflect on the conference ideas, develop action plans, and leverage these insights for the benefit of their business and clients."
Asteron Life commits to working alongside financial advisers who apply for the grant, assisting them in achieving their goals. "We aim to support advisers in realizing their plans and ensuring that the knowledge gained from the MDRT conference translates into tangible benefits," Arthur concluded.
The Asteron Life MDRT Grant Programme represents a significant step in fostering innovation and growth among financial advisers, reinforcing Asteron Life's dedication to the professional development of its adviser community.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Dec 03, 2024
Dec 03, 2024
Nov 29, 2024
Nov 29, 2024
Nov 28, 2024
Nov 28, 2024
Nov 27, 2024
Nov 27, 2024
Nov 26, 2024
Nov 26, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva New Zealand Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.